CGN Advisors LLC Acquires Shares of 35,072 Sanofi $SNY

Key Points

• CGN Advisors LLC has acquired a new stake in Sanofi, purchasing 35,072 shares valued at approximately $1,694,000 during the second quarter.
• Multiple institutional investors have increased their stakes in Sanofi, with Price T Rowe Associates raising its position by 1.8% and Federated Hermes increasing its stake by 58.5% in recent quarters.
• Analysts have generally upgraded their ratings on Sanofi, with Morgan Stanley and JPMorgan Chase both moving the stock from "equal weight" and "neutral" to "overweight", reflecting positive sentiment regarding the company’s growth prospects.

CGN Advisors LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 35,072 shares of the company's stock, valued at approximately $1,694,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in Sanofi by 1.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company's stock valued at $612,106,000 after buying an additional 193,196 shares in the last quarter. Federated Hermes Inc. raised its stake in Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock valued at $218,933,000 after buying an additional 1,456,269 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in Sanofi by 6.9% during the first quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company's stock valued at $181,764,000 after buying an additional 211,641 shares in the last quarter. Raymond James Financial Inc. raised its position in shares of Sanofi by 15.1% during the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company's stock worth $179,914,000 after purchasing an additional 425,597 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Sanofi during the 1st quarter worth approximately $177,831,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SNY. Morgan Stanley upgraded Sanofi from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $62.67.

Sanofi Stock Performance

SNY opened at $46.88 on Wednesday. The firm has a market cap of $115.11 billion, a PE ratio of 11.27, a P/E/G ratio of 1.11 and a beta of 0.51. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business has a fifty day simple moving average of $48.44 and a 200-day simple moving average of $50.64. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi's revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.73 EPS. As a group, equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.